Treace to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PONTE VEDRA, Fla., Dec. 20, 2022 - Treace Medical Concepts, Inc. (NasdaqGS: TMCI) announces that CEO John T. Treace and CFO Mark L. Hair will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 10:30 a.m. ET. Treace, a leader in bunion treatment, aims to shift surgical practices with its patented Lapiplasty® 3D Bunion Correction™ Procedure, addressing the needs of the estimated 1.1 million surgical candidates annually in the U.S. A live webcast of the presentation will be available on the company’s investor relations website.
Details
News Market Reaction – TMCI
The recorded move for TMCI in the trading session of this news was +1.48%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PONTE VEDRA, Fla., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will present the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 10:30 a.m. Eastern Time.
A live webcast and replay of the Company’s presentation will be available on the Investor Relations section of the Company’s website at https://investors.treace.com/. The webcast will be archived on the website following the completion of the presentation.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ System – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace recently expanded its offering with the Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide further support to hallux valgus patients. For more information, please visit www.treace.com.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
IR@treace.net
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.